Deep Value Reports

SPRY Stock Risk & Deep Value Analysis

ARS Pharmaceuticals, Inc.

DVR Score

8.3

out of 10

Hidden Gem

The Bottom Line on SPRY

We analyzed ARS Pharmaceuticals, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran SPRY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 28, 2025•Run Fresh Analysis →

SPRY Deep Value Analysis

SPRY targets a massive anaphylaxis market with neffy, a potential first-in-class needle-free epinephrine spray, offering significant patient benefits and market disruption. Strong cash runway post-PIPE financing and a resilient leadership team navigating regulatory setbacks demonstrate execution capacity. The upcoming PDUFA date (July 2024) is a critical, binary catalyst; approval would unlock substantial market share and multi-bagger potential. However, regulatory failure (reiterated by prior CRL) poses a showstopping risk, making this a high-risk, high-reward bet for 10x growth.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More